Pyxis Oncology is an immuno-oncology company focused on developing novel therapies to help patients defeat difficult to treat cancers. Built on the ground-breaking research of Dr. Thomas Gajewski, Pyxis is pursuing promising novel targets derived from the latest insights into the tumor microenvironment. Pyxis has generated preclinical data on these targets and is developing a pipeline of novel antibodies with the potential to help new patient populations not currently served by today’s immunotherapies. David Steinberg served as the company’s co-founder and CEO. Pyxis closed a $22 million Series A round of financing from the Leaps by Bayer, Longwood Fund, Agent Capital, Ipsen, and a group of other investors.